Education
About Us
Working with TipRanks
Follow Us
Mediwound (MDWD)
NASDAQ:MDWD
MDWD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$12.78 - $24.00
Previous CloseN/A
Volume29.05K
Average Volume (3M)72.66K
Market Cap
$221.34M
Enterprise ValueN/A
Total Cash (Recent Filing)$9.15M
Total Debt (Recent Filing)$6.51M
Price to Earnings (P/E)―
Beta0.97
Next Earnings
May 21, 2025EPS Estimate
-0.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.36
Shares Outstanding10,807,726
10 Day Avg. Volume95,525
30 Day Avg. Volume72,656
Financial Highlights & Ratios
PEG Ratio0.97
Price to Book (P/B)5.52
Price to Sales (P/S)0.00
P/FCF Ratio-9.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$27.67Price Target Upside34.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Mediwound News
PremiumCompany Announcements
MediWound Announces Key Approvals at 2025 Shareholder Meeting
PremiumCompany Announcements
MediWound Announces 2025 Annual General Meeting and Key Agenda Items
PremiumCompany Announcements
MediWound’s Earnings Call: Progress Amid Financial Challenges---
Bulls Say, Bears Say
Bulls Say
FundingMediWound received €16.5 million in funding from the European Innovation Council to accelerate the development of EscharEx in the DFU indication.
Market OpportunityEscharEx represents a potential $2.5 billion market opportunity for enzymatic debridement of chronic wounds in the outpatient setting.
Partnerships And CollaborationsMediwound has secured an additional collaboration for its DFU study, with Kerecis joining to contribute its MariGen Fish-Skin graft, representing additional validation for the potential of EscharEx.
Bears Say
Manufacturing CapacityGlobal demand for NexoBrid currently exceeds MDWD's manufacturing capacity by roughly threefold, a dynamic that will ease over the course of this year as manufacturing capacity ramps.
Regulatory ChallengesNexoBrid guidance tightened towards lower end, reflecting adjusted timelines for EU approval of the manufacturing facility.
Supply ConstraintsNexoBrid sales are limited only by supply, as demand for the product continues to exceed supply.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
1.96% Mutual Funds
24.81% Other Institutional Investors
68.78% Public Companies and Individual Investors
MDWD FAQ
What was Mediwound’s price range in the past 12 months?
Mediwound lowest stock price was $12.78 and its highest was $24.00 in the past 12 months.
What is Mediwound’s market cap?
Mediwound’s market cap is $221.34M.
When is Mediwound’s upcoming earnings report date?
Mediwound’s upcoming earnings report date is May 21, 2025 which is today.
How were Mediwound’s earnings last quarter?
Mediwound released its earnings results on Mar 19, 2025. The company reported -$0.36 earnings per share for the quarter, beating the consensus estimate of -$0.576 by $0.216.
Is Mediwound overvalued?
According to Wall Street analysts Mediwound’s price is currently Undervalued.
Does Mediwound pay dividends?
Mediwound does not currently pay dividends.
What is Mediwound’s EPS estimate?
Mediwound’s EPS estimate is -0.66.
How many shares outstanding does Mediwound have?
Mediwound has 10,807,726 shares outstanding.
What happened to Mediwound’s price movement after its last earnings report?
Mediwound reported an EPS of -$0.36 in its last earnings report, beating expectations of -$0.576. Following the earnings report the stock price went down -5.138%.
Which hedge fund is a major shareholder of Mediwound?
Currently, no hedge funds are holding shares in MDWD
---
Mediwound Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$27.67 (34.91% Upside)
$27.67 (34.91% Upside)
Blogger Sentiment
Bullish
MDWD Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 6.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 9.3%
Last 30 Days ▼ 9.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
18.44%
12-Months-Change
Fundamentals
Return on Equity
-96.33%
Trailing 12-Months
Asset Growth
10.59%
Trailing 12-Months
Company Description
Mediwound
Mediwound Ltd. is a biopharmaceutical company operating in the healthcare sector, focusing on the development, manufacturing, and commercialization of novel therapeutics for tissue repair and regeneration. The company's core products include innovative enzyme-based solutions designed to treat severe burns, chronic wounds, and other hard-to-heal injuries. Mediwound's flagship product, NexoBrid, is used for the removal of eschar in adults with deep partial- and full-thickness thermal burns.
---
MDWD Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant clinical and commercial progress, particularly with EscharEx and NexoBrid, along with strategic collaborations and a strong financial backing. However, the increased operating and net losses, along with a decline in gross margin, suggest financial challenges. The positive advancements in products and strategic partnerships indicate a promising outlook despite these financial hurdles.Read More>---
MDWD Stock 12 Month Forecast
Average Price Target
$27.67
▲(34.91% Upside)
Technical Analysis
---